Fulgent Genetics Ownership
| FLGT Stock | USD 17.78 0.35 1.93% |
Shares in Circulation | First Issued 2015-03-31 | Previous Quarter 30.7 M | Current Value 30.8 M | Avarage Shares Outstanding 23.1 M | Quarterly Volatility 6.9 M |
Fulgent Stock Ownership Analysis
About 33.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.49. Some equities with similar Price to Book (P/B) outperform the market in the long run. Fulgent Genetics has Price/Earnings To Growth (PEG) ratio of 1.32. The entity recorded a loss per share of 1.33. The firm had not issued any dividends in recent years. Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California. Fulgent Genetics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 645 people. To learn more about Fulgent Genetics call Ming Hsieh at 626 350 0537 or check out https://www.fulgentgenetics.com.Besides selling stocks to institutional investors, Fulgent Genetics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Fulgent Genetics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Fulgent Genetics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Fulgent Genetics Quarterly Liabilities And Stockholders Equity |
|
Fulgent Genetics Insider Trades History
About 33.0% of Fulgent Genetics are currently held by insiders. Unlike Fulgent Genetics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Fulgent Genetics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Fulgent Genetics' insider trades
Fulgent Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Fulgent Genetics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Fulgent Genetics backward and forwards among themselves. Fulgent Genetics' institutional investor refers to the entity that pools money to purchase Fulgent Genetics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Deutsche Bank Ag | 2025-03-31 | 269.8 K | Jpmorgan Chase & Co | 2025-03-31 | 257.9 K | Connor Clark & Lunn Inv Mgmt Ltd | 2025-03-31 | 249.7 K | Charles Schwab Investment Management Inc | 2025-03-31 | 244 K | Jane Street Group Llc | 2025-03-31 | 238.2 K | Invenomic Capital Management, Lp | 2025-03-31 | 236.2 K | Cubist Systematic Strategies, Llc | 2025-03-31 | 221.2 K | Trexquant Investment Lp | 2025-03-31 | 208.4 K | Goldman Sachs Group Inc | 2025-03-31 | 202.8 K | Blackrock Inc | 2025-03-31 | 2.2 M | Millennium Management Llc | 2025-03-31 | 2 M |
Fulgent Genetics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fulgent Genetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fulgent Genetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Fulgent Genetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Fulgent Genetics Outstanding Bonds
Fulgent Genetics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Fulgent Genetics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Fulgent bonds can be classified according to their maturity, which is the date when Fulgent Genetics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US359678AC31 Corp BondUS359678AC31 | View | |
| HB Fuller 4 Corp BondUS359694AB24 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Fulgent Genetics Corporate Filings
F4 | 11th of June 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 15th of May 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 13th of May 2025 Other Reports | ViewVerify | |
| 26th of March 2025 Other Reports | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Fulgent Stock Analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.